GCC IgA Nephropathy Disease Landscape

The GCC nephrology network capacity survey puts kidney biopsy at fewer than 30% of eligible proteinuric patients, versus roughly 70% in Japan and Germany — masking an estimated 8,000–12,000 IgA nephropathy patients inside the region's diabetes epidemic.

IgA nephropathy (IgAN) is estimated to affect 8,000–12,000 patients across the GCC, but the true IgAN fraction of incident CKD is difficult to establish: most proteinuric patients in the region are attributed to diabetic nephropathy, reflecting the GCC's 20–25% adult diabetes prevalence, without a confirmatory kidney biopsy. KDIGO guidance calls for biopsy in non-diabetic proteinuria, yet a GCC nephrology network capacity survey finds GCC nephrology practice performing biopsy in fewer than 30% of eligible proteinuric patients — versus roughly 70% in Japan and Germany. Under-biopsy is functionally equivalent to under-diagnosis: a patient never biopsied cannot be coded as IgAN, regardless of the underlying pathology.

Once diagnosed, GCC IgAN patients progress to end-stage renal disease 15–20% faster than European observational cohorts, a pattern consistent with later diagnosis (more advanced disease at confirmation), poorly controlled hypertension (mean systolic blood pressure at IgAN diagnosis: 148mmHg versus a sub-130mmHg target), and late initiation of ACE inhibitor or ARB therapy. Kidney biopsy capability itself is concentrated at fewer than 20 GCC centres with dedicated nephrology and interventional radiology teams; the patient journey from proteinuria detection through nephrology referral to biopsy typically adds 3–6 months per step, for a total of 12–24 months from proteinuria detection to IgAN diagnosis, roughly double the 6–12 month benchmark in Europe. GCC patients reaching ESRD represent a meaningful share of the region's 5,000-plus annual dialysis population, with IgAN contributing an estimated 12–15%.